ArticleJournal of endocrinological investigation2025
Results for LINAC-based radiosurgery or fractionated stereotactic radiotherapy for corticotropic pituitary tumors: a single-center retrospective cohort.
Article in Journal of endocrinological investigation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRadiotherapy (RT) plays an important role in the treatment of persistent or recurrent Cushing disease (CD) after primary surgery. We assessed the results for RT using a linear accelerator based (LINAC) stereotactic technique. Primary objectives were progression-free survival (PFS) and time to hormonal disease control (THC).
methodsSingle-center retrospective cohort in a tertiary, academic hospital assessed between 2008 and 2023.
resultsFifty-nine patients (59) patients were assessed. Mean age was 41.9 years (range: 15 to 72 years). Most were female (79.7%). Median lesion size at first visit was 1.49 cm (range: 0.3 to 5.2 cm). Patients were either treated with fractionated RT (50.8%) or single-fraction radiosurgery (SRS). Cabergoline was used prior (49.2%) and concurrently to RT (38.9%). Ketoconazole during SRT was also largely used (30.5%). Median follow-up was 69.9 months. There were no reported deaths. Median PFS was not reached, mean was 78.5 months. Disease control was reported in 94.9% of patients. Only 3 (5.1%) acquired new hormonal deficits. Univariate analysis showed that no variable impacted either PFS or tumor response. Criteria for hormonal remission at 12 months were reached in 33.9%. Median THC was 37.1 months (interquartile interval 25% 8.2 months to 75% 153.5 months). There were two new cardiac events during follow-up and new Cushing stigmata arise on two patients (3.3%).
conclusionWe achieved good results for LINAC-based RT in this large, single center cohort with high tumor control. Among patients with CD treatment options impacted neither PFS nor cure rate in this study.
Indexed as
Identifiers
40627080What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.